NEW YORK (GenomeWeb News) – The US Food and Drug Administration has approved Roche's companion diagnostic test for Tarceva (erlotinib), Roche announced Tuesday night.

Roche also said that FDA approved Tarceva as a first-line treatment for patients with metastatic non-small cell lung cancer whose tumors have certain epidermal growth factor receptor mutations as detected by the Cobas EGFR Mutation Test.

Tarceva is jointly marketed in the US by Roche's Genentech business and Astellas Pharma US, a subsidiary of Tokyo-based Astellas Pharma.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.